首页 | 本学科首页   官方微博 | 高级检索  
     


The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia
Authors:Yazed AlRuthia  Majid Almadi  Abdulrahman Aljebreen  Nahla Azzam  Wejdan Alsharif  Hala Alrasheed
Affiliation:1. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia;2. Pharmacoeconomics Research Unit, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia yazeed@ksu.edu.sa"ORCIDhttps://orcid.org/0000-0002-0029-5924;4. Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia;5. Division of Gastroenterology, The McGill University Health Center, Montreal General Hospital, McGill University, Montreal, Canada "ORCIDhttps://orcid.org/0000-0001-9917-2758;6. Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia "ORCIDhttps://orcid.org/0000-0001-5666-9588;7. Department of Medicine, Gastroenterology Division, King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia "ORCIDhttps://orcid.org/0000-0002-2097-289X;8. Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
Abstract:Abstract

Aims

This study’s objectives were to examine and compare the cost-effectiveness of biologic and non-biologic therapies in the improvement of the health-related quality of life (HRQoL) of patients with inflammatory bowel disease (IBD) in Saudi Arabia.
Keywords:Inflammatory bowel disease  Crohn’s disease  ulcerative colitis  drug costs  quality of life  infliximab  adalimumab  cost effectiveness  cost analysis  probabilistic sensitivity analysis
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号